FIELD: medicine.
SUBSTANCE: invention is intended for use in medicine, in particular in immunology, and can be used to obtain adjuvant antiviral vaccines against hepatitis B viruses or influenza. For this, fucoidan obtained from Fucus evanescens brown alga with a molecular weight of 130–430 kDa is used as an adjuvant, monosaccharide composition fucose:galactose:xylose in the ratio of 94.1:3.8:2.1 mol. %, the sulfate content of 27 %.
EFFECT: use of fucoidan with an established monosaccharide composition provides an adjuvant that enhances the immunogenicity of the hepatitis B surface antigen and influenza virus A.
1 cl, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
ADJUVANT | 2020 |
|
RU2736933C1 |
AGENT POSSESSING ANTIVIRAL ACTIVITY | 2006 |
|
RU2304443C1 |
METHOD FOR DISLIPIDEMIA PREVENTION | 2016 |
|
RU2621152C1 |
RECOMBINANT ANTI-INFLUENZA VACCINE WITH WIDE RANGE OF PROTECTION AND METHOD FOR ITS PREPARATION | 2017 |
|
RU2757013C2 |
VACCINE AND METHOD FOR INCREASING IMMUNOGENICITY AND SPECIFIC ACTIVITY OF INFECTION PREVENTION AGENTS | 2020 |
|
RU2741834C1 |
CROSS-REACTIVE RECOMBINANT HUMAN INFLUENZA A VIRUS VACCINE | 2020 |
|
RU2742336C1 |
VIRAL VACCINE | 2003 |
|
RU2268067C2 |
INFLUENZA VACCINE | 2014 |
|
RU2546861C1 |
IMMUNOGENIC SUBSTANCES CONTAINING ADJUVANT OF POLYINOSINE ACID AND POLYCYTIDYLIC ACID | 2006 |
|
RU2462264C2 |
IMMUNOGENIC COMPOSITION | 2005 |
|
RU2308289C2 |
Authors
Dates
2018-12-27—Published
2017-06-14—Filed